RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

What latest developments? The RD/Ampakine patent solidifies their IP position, but I have not been thinking that it was IP that was getting in the way of a partnership--it didn't stop Biovail, for example.

If someone in the cardio area comes to see the value of a CSA/CHF program; if Servier decides the Cortex Ampakine roster is better than their's--the value of Cortex will be considerably higher than it is now, not that this would be saying much. If you're asking for a number, I'm not going to suggest one, because it would be viewed as a target for attack by some, a reason for false solace by others--and with the pharma industry in a fugue state, rational criteria for assessing value are out the window. If they don't already have it inhouse, there is huge reluctance to bring in something mechanistically new. Their own jobs are on the line.

NeuroInvestment